Methods for in vivo drug delivery with porous nanostructures

• US 9,555,114 B2
• Filed: 09/19/2014
• Issued: 01/31/2017
• Est. Priority Date: 03/05/2003
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Sailor, Michael J., Abbi, Guarav, Collins, Boyce E., Dancil, Keiki-Pua S.
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): Tcherkasskaya, Olga V
• Application Number:
  US14/491,055
• Publication Number:
  US 20150011521A1
• Time in Patent Office: 865 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 9/0097 Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips intradermal microneedle arrays A61K9/0021; MEMS in general B81B7/02
• CPC Class Codes: C25F 3/14 locally
• CPC Class Codes: G01N 2021/7773 Reflection
• CPC Class Codes: G01N 2021/7776 Index
• CPC Class Codes: G01N 33/5438 Electrodes
• CPC Class Codes: G01N 33/552 Glass or silica

Abstract

A method of controlled in vivo drug delivery is provided. A porous silicon matrix having pores sized and configured to admit to trap and then release a predetermined molecular complex with a predetermined dose-time profile is selected. The matrix contains the predetermined molecular complex so that the predetermined molecular complex is disposed within the pores of the porous silicon matrix. The matrix is introduced into a human body. The drug releases according the dose-time profile. The introduction can be via transdermal introduction, intramuscular injection, intravenous introduction, surgical implantation, inhalation, and oral ingestion.

Claims

1. A method of controlled in vivo drug delivery comprising:

providing a porous silicon matrix prepared by electrochemically etching silicon in aqueous ethanolic hydrofluoric acid using an asymmetric electrode configuration and having a lateral pore gradient providing predetermined distribution and range of pore sizes configured to admit, trap and then release via diffusion out of the pores a predetermined molecular complex with a predetermined dose-time profile;

exposing said matrix to the predetermined molecular complex so that the predetermined molecular complex is admitted within the pores of said porous silicon matrix;

introducing the matrix comprising predetermined molecular complex to a human body.

2. The method of claim 1, wherein the predetermined molecular complex consists of at least one of an anticancer drug, a chronic pain medication, an anti-inflammatory drug, an anti-coagulant, and an anti-rejection drug.

3. The method of claim 1, wherein introducing the matrix comprises one of the group consisting of transdermal introduction, intramuscular injection, intravenous introduction, surgical implantation, inhalation, and oral ingestion.